Method for the reduction of glycemia



United States Patent Int. Cl. Alslk 27/00 US. Cl. 424-270 2 Claims This invention relates to the reduction of glycemia.

The present invention accordingly provides pharmaceutical compositions useful for reducing glycemia for prolonged periods comprising, as active ingredients, the compound of formula:

where X is hydrogen in association with a pharmaceutical diluent. The active ingredient preferably constitutes 5 to 95% by weight of the said composition.

Solid compositions for oral administration include compressed tablets, pills, powders, and granules. In such solid compositions the active compound is admixed with at least one inert diluent such as starch, ucrose or lactose. The compositions may also comprise, as is normal practice, additional substances other than inert diluents, e.g. lubricating agents, such as magnesium stearate. Liquid compositions for oral administration include pharmaceutically-accepta-ble emulsions, solutions, suspensions, syrups and elixirs containing inert diluents commonly used in the art, such as water and liquid parafiin. Besides inert diluents such compositions may also comprise adjuvants, such as wetting and suspending agents, and sweetening, flavoring, perfuming and preserving agents. The compositions according to the invention, for oral administration, also include capsules of absorbable material such as gelatin containing one or more of the active substances with or without the addition of diluents or excipients.

The percentage of active ingredient in the compositions of the invention may be varied, it being necessary that it should constitute a proportion such that a suitable dosage shall be obtained. The dosage will depend upon the therapeutic effect sought, the route of administration, the length of treatment, and the size and species of animal. In human therapy the compositions should generally be 3,449,499 Patented June 10, 1969 administered so as to give, in the case of oral administration, between 500 mg. and 2 g. of active substance per day.

A preferred form of tablet for use in accordance with the invention has the following composition.

2-benzenesulphonylamino-S-t-butyl-lthia-3,4-diazole 250 Potato starch 6 Talc 3 Magnesium stearate 0.5 Wheat starch to 330 The invention also provides a method of reducing glycemia for prolonged periods which comprises administering to an animal organism a compound of the above formula in amount suflicient to reduce the glycemia. It is an advantage of the invention that a single daily dose only need be given, because of the prolonged action of the compounds characteristic of the new method. Ordinarily a dose of 5 to 40 mg. per kg. of animal organism will be administered, corresponding to a dose of about 0.5 to 2.0 g. for an average size adult. Such a dosage will maintain the glycemia of a diabetic patient at about the normal level for at least 24 hours.

I claim:

1. A method of treating diabete which comprises administering orally to a human diabetic patient Z-benzenesulphonylamino-S-t-butyl-1-thia-3,4-diazole in a single daily dose of 5 to 40 milligrams per kilogram of said patient.

2. A method of treating diabetes which comprises administering orally to a human diabetic patient 2-benzenesulphonylamino-5-t-butyl-1-thia-3,4-diazole in a daily dose of 5 to 40 milligrams per kilogram of said patient.

References Cited UNITED STATES PATENTS 3,121,089 2/1964 Jansson.

FOREIGN PATENTS 822,947 11/1959 Great Britain. 824,978 12/1959 Great Britain.

ALBERT T. MEYERS, Primary Examiner.

J. D. GOLDBERG, Assistant Examiner. 

1. A METHOD OF TREATING DIABETES WHICH COMPRISES ADMINISTERING ORALLY TO A HUMAN DIABETIC PATIENT 2-BENZENESULPHONYLAMINO-5-T-BUTYL-1-THIA-3,4-DIAZOLE IN A SINGLE DAILY DOSE OF 5 TO 40 MILLIGRAMS PER KILOGRAM OF SAID PATIENT. 